Xuan Gu Bao·2025-10-29 14:47Group 1 - Eli Lilly and Nvidia announced a collaboration to build the pharmaceutical industry's most powerful supercomputer and AI factory, aimed at accelerating drug development processes [1] - The supercomputer is expected to be completed by December and operational by January, consisting of over 1,000 Nvidia Blackwell Ultra GPU chips connected through a unified high-speed network [1] - The AI factory will utilize this supercomputer to develop, train, and deploy AI models for drug research, enhancing the identification of potential drug targets and assisting in drug molecule design [1] Group 2 - The AI pharmaceutical market in China is projected to grow from 730 million to 5.86 billion yuan from 2024 to 2028, with a compound annual growth rate of 68.5% [1] - Lijun Group has strengths in oncology, reproductive health, gastrointestinal, and psychiatric medications, and has invested in AI drug design technology developer Infiniz [2] - Hongbo Pharmaceutical combines AI algorithms with drug design to improve research efficiency, focusing on large-scale virtual screening and predicting drug metabolism properties [2]